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-e duplication of 5′ segment of KMT2A is a rare molecular event in childhood leukemia, and the in0uence on prognosis is
unknown. Here, we report on a boy who developed acute monocytic leukemia. Fluorescence in situ hybridization revealed the
duplication of the 5′ segment with 2 normal alleles at KMT2A which was eventually found to be fused with MLLT10. Che-
motherapy promptly induced the 2rst complete remission in the patient at our facility, and the patient remained in 2rst complete
remission with negative minimal residual disease at 3.5 years from diagnosis. Our case is similar to two previously reported
patients who had partial duplication of the 5′ segment of KMT2A with a KMT2A-MLLT10 rearrangement. Further studies and
experience with this cryptic translocation may shed more light on the management of acute myeloid leukemia.
1. Introduction
-e histone-lysine N-methyltransferase 2A enzyme (MLL1),
encoded by the KMT2A gene, is an upregulator of global,
hematopoietic gene transcription, and translocation rear-
rangement within KMT2A causes variable risk strati2cation
in acute leukemia based on the 2nal genetic outcome.
Patients withMLL rearrangement other than t(9;11) and
t(11;19) have an inferior outcome [1], and there are addi-
tional aberrations in KMT2A rearrangement, such as fusion
with preferential partner gene MLLT10, that also carry
prognostic signi2cance [2].
One of these aberrations is the duplication/ampli2cation
of the 5′ segment of KMT2A, which is a very rare molecular
event, and the in0uence of this on patient prognosis is
unknown. However, in general, KMT2A ampli2cation as an
acquired genetic aberration has been reported to result in
a poor prognosis [3]. With this deleterious e?ect of KMT2A
overexpression in acute leukemia in mind, it is possible that
even partial ampli2cation could a?ect the patient’s prog-
nosis. In the literature, only 2 cases have been reported: one
pediatric case of AML-M5b(FAB: French-American-British
Classi2cation) with the duplicated 5′ segment of KMT2A
relapsed 16 months after diagnosis during maintenance
therapy and was later salvaged by allogeneic transplantation
[4] and an adult case of AML-M5a(FAB) with an ampli2ed 5′
part of 11q23.3 where KMT2A was located eventually needed
transplantation [5]. In both literature cases, this partial du-
plication was paired with KMT2A-MLLT10 rearrangement.
Although preferential fusion withMLLT10 has been well
documented, the isolated prognostic importance of the
partial ampli2cation of KMT2A remains unknown. Here, we
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present the case of a pediatric male patient with AML who
was successfully treated by multiagent chemotherapy alone.
-e 5′ duplication of KMT2A was identi2ed by 0uorescence
in situ hybridization (FISH) before treatment, but fusion to
MLLT10 was discovered by RNA sequencing after com-
pletion of the treatment even though reverse transcription-
PCR at the diagnosis did not detect any fusion partners.
2. Case Description
A 6-year-old boy was admitted with complaints of low-grade
fever, multiple joint pain, skin rash, and neutropenia. A
complete blood count was conducted; leukocytes were
1.6×109/L, hemoglobin was 9.1 g/dl, and platelet count was
222×109/L. -e bone marrow was replaced by 90% mono-
blasts. Flow cytometry was conducted on the leukemic cells.
HLA-DR, CD58, CD99, CD56, CD38, cy-MPO, CD11b, CD13,
CD33, CD65, CD64, CD117, CD36, CD61, CD4, and 7.1 were
positive, and CD14, CD15, CD19, CD10, CD20, CD3, and CD7
were negative. He was diagnosed with AML (FABM5a). FISH
analysis using a KMT2A locus-speci2c dual-color DNA probe
(Vysis LSI MLL Dual Color, Break Apart Rearrangement
Probe, Abbott Laboratories, IL, USA) was used to characterize
the partial 5′ duplication and 2 other normal KMT2A alleles
(Figure 1). Cell culture for chromosomal analysis failed. -e
search for KMT2A-MLLT10 fusion was performed according
to a publication previously reported [6]. Reverse transcription-
polymerase chain reaction of major fusion partners to KMT2A
(includingMLLT10) was conducted and none were ampli2ed.
-e primer for KMT2A was designed in exon 8.
Final diagnosis, in this case, was AMLwith 11q23/KMT2A
abnormalities (FAB M5a) without any con2rmation of
partner genes. As he presented no abnormalities such as
t(8;21), inv(16), -7, 5q-, t(16;21) (p11;q22), Ph1, and FLT3-ITD,
he underwent multimodal chemotherapy for the intermediate
risk group according to JPLSG AML05, which consists of
induction 1 (ECM: etoposide 150mg/m2/day on days 1–5,
cytarabine 200mg/m2/day on days 6–12, mitoxantrone
5mg/m2/day on days 6–10, and intrathecal chemotherapy on
day 6), induction 2 (HCEI: cytarabine 3 g/m2 every 12 hours
on days 1–3, etoposide 100mg/m2/day on days 1–5, idarubicin
10mg/m2/day on day 1, and intrathecal chemotherapy on
day 1), and 3 intensi2cation therapy (HCM: cytarabine 2 g/m2
every 12 hours on days 1–5, mitoxantrone 5mg/m2/day on
days 1–3, and intrathecal chemotherapy on day 1; HCEI; and
HCM) [7]. -e chemotherapy promptly induced a 2rst
complete remission in the patient which has persisted 3.5
years from diagnosis without hematopoietic stem cell
transplantation.
RNA sequencing on NextSeq500 (Illumina, Inc., CA,
USA) was then used to screen for fusion partners, revealing
a KMT2A-MLLT10 rearrangement. -e RNA analysis was
conducted as follows: RNA was puri2ed from the patient’s
bone marrow at diagnosis using ISOGEN (Nippon Gene
Co., Ltd., Tokyo, Japan) according to the manufacturer’s
instructions. A sequencing library was then generated from
500 ng of total RNA using a TruSeq Stranded mRNA Library
Prep Kit v2 (Illumina) according to the manufacturer’s
instructions. Next, sequencing was conducted at i-Labora-
tory LLP (Ibaraki, Japan). Obtained reads were aligned
(a) (b)
Figure 1: FISH and RT-PCR of the KMT2A rearrangement. (a) FISH of theKMT2A break apart signal: the green signal shows the 5′ segment,
and the red signal shows the 3′ segment of KMT2A. FISH revealed 2 normal signals (arrowhead) and 1 additional 5′ segment (arrow). Positive
cells with duplication of the 5′ segment of KMT2 were observed in 686 out of 1000 cells. (b) -e characterization of KMT2A-MLLT10 fusion
transcript at bone marrow by RT-PCR. 1: ladder; 2: normal control; 3: at diagnosis; 4: after induction therapy 1; 5: after induction therapy 2; 6:
after intensi2cation 1; 7: after intensi2cation 2; 8 and 9: after intensi2cation 3.
Table 1: All sequencing data for breakpoint.
catcaaaccaattaaacctgtcactagaaacaaggcaccccaggaacctccagtaaagaaaggacgtcgatcgaggcggtgtgggcagtgtcccggctgccaggtgcctgaggactgtggtgtttgtacta
attgcttagataagcccaagtttggtggtcgcaatataaagaagcagtgctgcaagatgagaaaatgtcagaatctacaatggatgccttccaaagcctacctgcagaagcaagctaaag(breakpoint)
aggtatttataacagcaatgatgtagcagtatcgtttccaaatgtagtatctggctcgggatctagtactcctgtctccagctctcacttacctcagcagtcttctgggcatttgcaacaagtaggagcgctctctc
cctcagctgtgtcatctgcagcccctgctgttgctacaactcaggcaaatactctatctggatcttctctcagtcaggcaccatctcatatgtatggcaatagatcaaattcatcaatggcagctcttatagctcag
tctgaaaacaatcaaacag
Underlined sequencing was from KMT2A, and nonunderlined sequencing was from MLLT10.
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toward human genome assembly hg19, and fusion gene
analysis was conducted with CLC Genomics Workbench
Ver. 7.5.1 software (Qiagen, Venlo, Netherlands). Four se-
quencing tags supporting KMT2A-MLLT10 rearrangement
were obtained, which were then con2rmed by Sanger se-
quencing. All sequencing data are shown in Table 1. Designed
primers were 5′-TCAATTGCTGGCTCAGAAGA-3′ (KMT2A
exon 5) and 5′-CTGAGCTATAAGAGCTGCCATT-3′
(MLLT10 exon 16). -e KMT2A breakpoint was located on
intron 6, which was the upstream region of the sequencing
primer for screening at diagnosis, and theMLLT10 breakpoint
was located on exon 14. Minimal residual disease (MRD) by
reverse transcription-polymerase chain reaction (RT-PCR)
was assessed from diagnosis as shown in Figure 1. Al-
though MRD was positive at diagnosis, it changed to negative
after induction therapy 1.
3. Discussion
Pediatric acute myeloid leukemia is classi2ed by chromo-
somal and/or genetic abnormalities according to the World
Health Organization Classi2cation published in 2008.
Chimeric genes including KMT2A rearrangements are used
to predict disease outcome. KMT2A rearrangements are
seen in about 20% of pediatric AML and are associated with
poor outcome, while the disease outcome depends on its
partner gene [1]. KMT2A has many partner genes, and each
chimeric gene has a di?erent prognosis.
It is diOcult to quantify the e?ect of the partial
duplication/ampli2cation of KMT2A as the two patients
previously reported had the same rearrangement of
KMT2A-MLLT10 with di?erent treatment outcomes. A
single abnormality within ampli2cation of KMT2A is re-
ported to have a gain-of-function e?ect for leukemogenesis
[3]; however, the exact role of this “partial” duplication of
KMT2A in acute leukemia is still unclear.
It is interesting to note that both previously reported
and the current cases have the same rearrangement along
with this partial duplication/ampli2cation and diagnosis of
FAB M5. Hence, we hypothesize that the leukemic cells
that partially duplicate KMT2A tend to undergo KMT2A-
MLLT10 fusion and may act more similarly to KMT2A-
MLLT10 rearrangements caused by the insertion of
KMT2A in chromosome 10p or an unbalanced translocation.
-is points to di?erent causes producing the same prognostic
e?ect. Similar rearrangement and the duplication of the 5′
segment of KMT2A might result in cell culture diOculties in
other cases.-erefore, we can recommend using FISH assays to
detect partial KMT2A duplication, and RNA sequencing may
be useful to specify the fusion partner in such cases.
4. Conclusion
Partial duplication of the 5′ segment of KMT2A can be easily
detected by FISH, but the crucial details of the KMT2A-
MLLT10 rearrangement may remain hidden from standard
PCR testing, which might result in poor prognosis.
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